Neosynthesis and Activation of Rho by *Escherichia coli* Cytotoxic Necrotizing Factor (CNF1) Reverse Cytopathic Effects of ADP-ribosylated Rho*

(Received for publication, May 24, 1999)

Holger Barth‡, Claudia Olenik‡, Peter Sehr, Gudula Schmidt, Klaus Aktories§, and Dieter K. Meyer¶

*From the Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg, Germany*

The low molecular mass GTPases of the Rho family (Rho, Rac, and Cdc42) play key roles in the control of the actin cytoskeleton (1). In several cell lines, activation of RhoA induces formation of stress fibers and focal adhesions (2), whereas Rac and Cdc42 cause the formation of lamellipodia and filopodia, respectively (2–4). Moreover, Rho GTPases act as molecular switches in various signaling processes (5) including secretion (6), phagocytosis (7), endocytosis (8, 9), cell cycle progression (10), transcriptional activation (11), and transfor-
mation (12).

Rho proteins are the eukaryotic targets of various bacterial toxins that inactivate or activate the GTPases by covalent modification (13). Whereas the large clostridial cytotoxins (*e.g.* *Clostridium difficile* toxins A and B) inactivate Rho GTPases by glucosylation at Thr35/37 (14, 15), the cytotoxic necrotizing factor from *Escherichia coli* (*E. coli* CNF1) activates the GTPases by deamidation of Gln61/63 (16–18). Moreover, RhoA, -B, and -C but not Rac1 and Cdc42 are substrates of exoenzyme C3 from *Clostridium botulinum* (19–21) or *Clostridium limosum* (22), which inactivates the GTPases by ADP-ribosylation at Asn41 (22). C3 exoenzyme in particular is widely used as a cell biological tool to study the functions of Rho (23).

Inasmuch as C3 exoenzyme appears to enter cells via nonspecific pinocytosis, its cell accessibility is poor (24). Recently, we constructed a C3 fusion toxin, which enters cells by using the binary *C. botulinum* C2 toxin as a carrier (25). The actin-ADP-ribosylating C2 toxin consists of the ~80-kDa binding component (C2II) and the 49-kDa enzymatic component (C2I) (26–28). Both C2 components are separate proteins which assemble at the cell surface after C2II has bound to an unknown receptor. The C3 fusion toxin (C2IN-C3) contains the N-terminal domain (amino acid residues 1–225) of C2I (C2IN), which has no enzyme activity but binds to the C2II component and is sufficient for translocation of C2I into the cytosol. In contrast to C3 exoenzyme, the C2IN-C3 fusion toxin enters cells readily and causes the depolymerization of stress fibers at low toxin concentration within a few hours (25). Thus, C2IN-C3 allows the study of the kinetics of the cellular intoxication process in more detail.

Here we report that the cytopathic effects of the C2IN-C3 fusion toxin are rapidly reversed after removal of the toxin. Reversal of the C3-induced alterations of the cytoskeleton is caused by rapid degradation of the toxin and by resynthesis of Rho. Moreover, we show that the Rho-deamidating toxin CNF1 reverses the effects of C2IN-C3 most likely by reactivating ADP-ribosylated Rho. The data provide new insights into the mechanism of the action of C3 and indicate that ADP-ribosylated Rho is still able to interact with effectors and to activate their targets.

**EXPERIMENTAL PROCEDURES**

**Materials and Chemicals—**Cell culture medium was purchased from Biochrom (Berlin, Germany), fetal calf serum from PAN Systems (Aidenbach, Germany) and Life Technologies, Inc. (Heidelberg, Germany), and cell culture materials from Falcon (Heidelberg, Germany). Lab-Tec chamber slides were from Permanox (Nunc, Germany). The C2I binding component from the *C. botulinum* C2 toxin was purified and activated with trypsin as described (26, 29). The C2IN-C3 fusion toxin (25)
FIG. 1. Time course of the effects of C2IN-C3/C2II on astroglial cells in primary culture. A, toxin effects are shown on cells morphology and the actin cytoskeleton. Cells grown on Lab-Tec chamber slides were incubated with C2IN-C3 (100 ng/ml) and C2II (200 ng/ml) in the medium. At the indicated times, cells were fixed and the actin filaments were stained with rhodamine-phalloidin. Some flat polygonal cells are visualized by dashed lines. Upper part, phase contrast pictures; lower part, rhodamine-phalloidin staining of the actin filaments of the respective cells. Bar = 50 mμ. B, ADP-ribosylation of Rho by C2IN-C3/C2II treatment of astroglial cells. Cells were treated without toxin (lane 1) or with C2IN-C3/C2II for 20 min (lane 2), 40 min (lane 3), 60 min (lane 4), 90 min (lane 5), and 120 min (lane 6), respectively. After toxin treatment, the cells were lysed and lysate proteins (100 μg) were subjected to an in vitro [32P]ADP-ribosylation assay with C3 as described under "Experimental Procedures." Labeled proteins were detected by SDS-PAGE and autoradiography. C, anti-RhoA immunoblot analysis of 100 μg of the same lysates described above. ADP-ribosylated RhoA is indicated by an asterisk.

and CNF1 (16) were purified as recombinant GST fusion proteins as described. The pGEX-LBC construct was kindly donated by Denniz Tokoöz, Harvard Medical School, Boston, MA (30). LBC was purified as a recombinant GST fusion protein. 2'-3'-(O,N-Methylanthraniloyl)guanosine 5'-diphosphate (mant-GDP) was prepared as described (31). The pGEX2T vector (included in the GST Gene Fusion System) and glutathione-Sepharose 4B were from Amersham Pharmacia Biotech (Uppsala, Sweden). Anti-RhoA-antibody and horseradish peroxidase-coupled anti-mouse antibody were from Santa Cruz (Heidelberg, Germany). Rhodamine-phalloidin, puromycin and cycloheximide were purchased from Sigma (Deisenhofen, Germany). [32P]NAD (30 Ci/ml) was from NEN Life Science Products (Bad Homburg, Germany). Nylon membrane for RNA blotting, the DIG in vitro transcription kit, and the DIG DNA labeling and detection kit were from Roche Molecular Biochemicals (Mannheim, Germany). Lactacystin was from Calbiochem (Bad Soden, Germany).

Cell Culture—CHO-K1 cells were cultivated in tissue culture flasks at 37 °C and 5% CO2 in Ham’s F-12/Dulbecco’s modified Eagle’s medium (1:1) containing 5% heat-inactivated (30 min, 56 °C) fetal calf serum, 2 mM l-glutamate, 100 units/ml penicillin, and 100 μg/ml streptomycin. Cells were routinely trypsinized and reseeded twice a week. Primary cultures of rat astroglial cells were set up as described previously (32, 33). For cytotoxicity and regeneration assays, subconfluent cells (about 105 to 5 x 106 cells/cm2) were grown on Lab-Tec chamber slides or cells growing on Lab-Tec chamber slides were treated for different times with 200 ng/ml activated C2II together with 100 ng/ml C2IN-C3. CNF1 was used in a final concentration of 300 ng/ml medium. For regeneration assays cells were treated with the respective toxins for 3 h, then the cells were washed 5 times with prewarmed medium, new medium without any toxin was added, and the cells were incubated at 37 °C.

Actin Staining—For fluorescence staining of F-actin, cells were fixed in 4% paraformaldehyde containing 0.1% Triton X-100 for 30 min. Thereafter, cells were briefly washed and incubated for 30 min with rhodamine-phalloidin (600 ng/ml).

ADP-ribosylation Assay of Rho—Cells were treated with the respective toxins as indicated. After incubation they were washed with cold PBS, harvested in 400 μl of cold lysis buffer (2 mM MgCl2, 0.1 mM

phenylmethylsulfonyl fluoride, 20 μg/ml leupeptin, 80 μg/ml benzamidine in 50 mM HEPES, pH 7.4) and sonicated. Aliquots (100 μg of protein) of the lysate were incubated with [32P]NAD and 50 ng of C2IN-C3 fusion toxin at 37 °C for 30 min, Laemmli buffer was added, the samples were heated for 3 min at 95 °C and run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). [32P]ADP-ribosylated proteins were detected by autoradiography with a Phospholimager from Molecular Dynamics (Krefeld, Germany).

SDS-PAGE and Western Blotting—SDS-PAGE was performed according to Laemmli (34). For immunoblot analysis, the proteins were transferred onto a nitrocellulose membrane. The membrane was blocked for 30 min with 5% nonfat dry milk in PBS containing 0.05% Tween 20 (PBS-T) and the proteins were probed with anti-RhoA antibody (mouse, 1:2000 in PBS-T). After washing with PBS-T, the blot was incubated for 1 h with an anti-mouse antibody coupled to horseradish peroxidase (1:2000 in PBS-T). The membrane was washed again, and proteins were visualized using the ECL system according to the manufacturer’s instructions.

Extraction and Filter Hybridization of RNA—Total RNA was extracted by the guanidinium hydrochloride method (35). Seven-μg aliquots were separated by denaturing gel electrophoresis (1.25% formaldehyde agarose gels; running buffer was 20 mM MOPS, 8 mM NaAc, and 1 mM EDTA) and electroblotted onto a nylon membrane. The following non-radioactive DIG filter hybridization and detection of RhoA mRNA was performed as described previously (36, 37).

Fluorescence Assay for Nucleotide Exchange—All measurements were done on a LS50B spectrophotometer from Perkin Elmer at 37 °C. First, RhoA was loaded with the fluorescent nucleotide mant-GDP by incubating 0.5 μM GTPase with 2 μM mant-GDP in buffer C (10 mM triethanolamine, pH 7.5, 150 mM NaCl, 2 mM MgCl2) for 1 h. Thereafter, the exchange of Rho-bound mant-GDP for GTP was initiated by adding 100 μM GTP and 0–20 μM LBC. The exchange of Rho-bound fluorescent mant-GDP for GTP was monitored by the decrease in fluorescence intensity upon the release of mant-GDP from RhoA. Exciting of the mant-fluorophor was at 357 nm; emission was measured at 444 nm. The rate constant for the release of mant-GDP was determined by fitting the experimental curve with a single exponential decay using SigmaPlot (Jandel Scientific).

RESULTS

C2IN-C3 Fusion Toxin Rapidly Disassembles Stress Fibers in Rat Astroglial Cells—In primary cultures of rat astrocytes, C2IN-C3 fusion toxin caused changes in cell shape and destruction of stress fibers. These effects started 40 min after addition.
of the toxin and were maximal about after 2 h (Fig. 1A). By 40–60 min after addition of C3 fusion toxin to intact cells, radioactive [32P]ADP-ribosylation of Rho was no longer observed in the cell lysate, indicating the complete modification of cellular Rho (Fig. 1B). The ADP-ribosylation of RhoA was confirmed by anti-RhoA immunoblot analysis (Fig. 1C). Twenty minutes after addition of the toxin, a fast moving (unmodified Rho) and a slower moving RhoA band (ADP-ribosylated Rho) were detected by immunoblotting. After 40 min, only the ADP-ribosylated RhoA was observed.

Effects of the C2IN-C3 Fusion Toxin Are Reversible—To test whether the effects of the fusion toxin were reversible, astroglial cells were incubated with the toxin for 3 h. Thereafter, the cells were extensively washed to remove extracellular toxin. Stress fibers reappeared 6 h after removal of the toxin, and the recovery was complete after 24 h (Fig. 2A). Reorganization of stress fibers was accompanied by the reappearance of the polygonal cell morphology (Fig. 2A). Removal of the toxin rapidly changed the proportion of ADP-ribosylated and non-modified Rho (Fig. 2B). Four hours after removal of the toxin, i.e., when the cells started to rebuild their stress fibers, a small amount of Rho was [32P]ADP-ribosylated. Its level increased with the duration of toxin withdrawal (Fig. 2B). Accordingly, 4 h after removal of the toxin, non-ADP-ribosylated RhoA was detected by anti-RhoA immunoblotting and 24 h after toxin withdrawal only non-ADP-ribosylated RhoA was detected (Fig. 2C).

Reversal of the C3 effects was not cell type-specific. In CHO cells or HeLa cells, the C3 fusion toxin disassembled stress fibers within 3 h. Removal of the toxin resulted in the reorganization of stress fibers, adhesion to dish matrix, and restoration of cell morphology. The recovery started 2–3 h after addition of fresh medium (data not shown). Reversal of the cytopathic effects seemed to be specific for the fusion toxin. When CHO cells were treated with 10 μg/ml wild-type C. limosum C3 exoenzyme for 24 h to induce the “C3 specific” morphology, cells did not recover after removal of the toxin by medium exchange.

Studies on the Duration of Action of the C2IN-C3 Fusion Toxin—Because the cytopathic effects disappeared rapidly after removal of C2IN-C3 from the medium, we studied whether the toxin was intracellularly degraded by proteases. When CHO cells were treated for 3 h with the fusion toxin and subsequently incubated for 16 h in fresh medium in the presence of the proteosome inhibitor lactacystin, cells did not regain their original morphology. In lysates of these cells, Rho was not radioactively labeled by ADP-ribosylation with [32P]NAD and C3 (Fig. 3A, lane 5). As expected, only a slowly migrating RhoA band was detected by immunoblotting, indicating the presence of Rho ADP-ribosylated in intact cells (Fig. 3B, lane 5). Thus, lactacystin prolonged the cellular effects of the C3 fusion toxin.

Studies on the Recovery of RhoA—First, we tested whether recovery of non-ADP-ribosylated Rho was due to cleavage of the ADP-ribose moiety from Rho by a cellular hydrolase activity. CHO cells were treated with the C3 fusion toxin for 2 h and then incubated for 1 h in fresh medium without toxin. Cell lysates were prepared and incubated for 0, 3, and 6 h at 37 °C.
lactacystin. ADP-ribosylated RhoA is indicated by an asterisk with C2IN-C3/C2II followed by a 16-h incubation in fresh medium; lane 5, 3-h incubation with C2IN-C3/C2II followed by a 16-h incubation in fresh medium + lactacystin. ADP-ribosylated RhoA is indicated by an asterisk.

Thereafter, Rho protein was analyzed by immunoblotting (Fig. 4). Even after incubation of the lysates for 6 h at 37 °C (Fig. 4, lanes 3 and 6), a significant proteolysis of RhoA was not detected. Furthermore, in lysates of cells that had been treated with C3 fusion toxin (lanes 4–6), the slowly migrating band of ADP-ribosylated RhoA remained stable, while a rapidly migrating RhoA band did not appear. Taking these results together, we were not able to detect hydrolysis of the ADP-ribosylated RhoA in the lysates.

To test whether the reappearance of non-ADP-ribosylated RhoA after toxin withdrawal was due to newly synthesized protein, we blocked protein synthesis with cycloheximide or puromycin. Three hours after addition of the toxin, endogenous Rho was completely ADP-ribosylated (no [32P]ADP-ribosyla-
tion, Fig. 5B, lane 2) and only the slowly moving ADP-ribosylated RhoA band was detected in the immunoblot (Fig. 5C, lane 2). When cycloheximide or puromycin was present after toxin withdrawal, regeneration of stress fibers (Fig. 5A) and [32P]ADP-ribosylation of Rho was not observed (Fig. 5B, lanes 5 and 7). Moreover, the immunoblot did not show unmodified RhoA (Fig. 5C, lanes 5 and 7). All these data suggested that protein neosynthesis, not hydrolysis of ADP-ribosylated RhoA, was responsible for the reappearance of non-ADP-ribosylated RhoA.

Northern blot analysis of total RNA extracts from CHO cells was used to investigate whether the rapid neosynthesis was initiated by an increase in RhoA mRNA. Neither addition of the C3 toxin (added for 3 h) nor its removal had any effect on the amount of RhoA mRNA (Fig. 6). Apparently, neosynthesis of RhoA protein is due to ongoing protein synthesis.

C3-induced Destruction of the Actin Cytoskeleton Is Prevented and Rapidly Reversed by CNF1—Because a small amount of newly synthesized RhoA protein appeared to induce the complete reassembly of actin filaments and reconstitution of the cellular morphology, we tested whether this process could be enhanced by incubation of C3-treated cells with the E. coli cytotoxic necrotizing factor, CNF1, which activates Rho by deamidation (16, 18). Therefore, actin stress fibers of CHO cells were destroyed by treatment (3 h) with the C3 fusion toxin (Fig. 7). The cells were subsequently incubated for 2 h with CNF1 in the presence of the C3 fusion toxin. Surprisingly, the cells started to form actin stress fibers as early as 60 min after CNF1 addition. The CNF1-induced rearrangement of the actin cytoskeleton was accompanied by a total reconstitution of “normal” cell morphology within about 2 h. CNF1 completely prevented the C3-induced breakdown of actin filaments when CNF1 was added 3 h prior to C2IN-C3 fusion toxin (data not shown). When both toxins were added together at the same time, a weak C3-induced disassembly of actin filaments was observed after 60 min. This effect was completely reversed by CNF1.
within another 60 min. The same rapid recovery of actin stress fibers was observed when NIH 3T3 fibroblasts were exposed to the various toxin combinations (data not shown).

C3-induced ADP-ribosylation of Rho in the Presence of CNF1—Next we analyzed the extent of ADP-ribosylation of Rho after CNF1 treatment. As shown in Fig. 8, in C3-treated cells RhoA remained completely ADP-ribosylated even after treatment of cells with CNF1 for 3 h (lane 4) (note that at this time point all cells exhibited complete recovery of the actin cytoskeleton). Additionally, when C2IN-C3 and CNF1 were added together, RhoA was ADP-ribosylated (lane 5). After 3 h, the cells showed no disassembly of stress fibers or C3-typical cytopathic effects on cell morphology. Finally, preincubation of cells with CNF1 for 3 h did not prevent C3-induced ADP-ribosylation. Similar results were obtained with NIH 3T3 cells (data not shown).

The effects of CNF1 on the C3-induced alteration of cellular morphology occurred very rapidly, suggesting that the recovery of cell morphology was not caused by neosynthesis of Rho. However, to exclude that CNF1 accelerated the expression of Rho and to rule out that a very small amount of neosynthesized RhoA was sufficient for rebuilding of the actin cytoskeleton, we tested the toxin in combination with inhibitors of protein synthesis. Therefore, CHO cells were treated for 16 h with the C3 fusion toxin in the presence of cycloheximide. Subsequently, the cells were incubated with CNF1 for another 2 h in the presence of cycloheximide. Thereafter, cells were lysed and Rho was [32P]ADP-ribosylated by C3. Fig. 9A shows that no radioactive labeling of Rho was detected in lysates of cells pretreated with C3 or C3 plus CNF1. In contrast, pretreatment of cells with CNF1 did not inhibit the radiolabeling of Rho. These findings indicated that Rho from cells treated with fusion toxin and additionally with CNF1 was completely ADP-ribosylated. The anti-RhoA immunoblot (Fig. 9B) confirmed the ADP-ribosylation of RhoA and showed an additional shift of Rho due to CNF1-induced modification. Taken together, these results demonstrated that, despite the ADP-ribosylation of cellular Rho, CNF1 treatment causes complete and rapid reorganization of the actin cytoskeleton, even under conditions excluding the de novo synthesis of Rho.

Effect of ADP-ribosylation on Nucleotide Exchange of RhoA Activated by the Exchange Factor LBC—The results described above (e.g. activation of ADP-ribosylated Rho by CNF1) suggested that inhibition of Rho function by ADP-ribosylation is not caused by a blockade of the interaction of the GTPase with its effectors but rather by inhibition of its activation. To test this hypothesis, we studied the nucleotide release of ADP-ribosylated Rho previously loaded with mant-GDP in the presence of the Rho-specific nucleotide exchange factor LBC (30).

As shown in Fig. 10A, the release of mant-GDP of control RhoA was stimulated by GST-LBC by about 13-fold, whereas LBC stimulated the release of the nucleotide from ADP-ribosylated Rho only by about 1.5-fold. This dramatic reduction in the activation of GDP release was observed over a broad concentration range of LBC (Fig. 10B).

DISCUSSION

To study kinetics and functional consequences of Rho ADP-ribosylation in intact cells, we used the C2IN-C3 fusion toxin that uses the cell delivery system of the binary C. botulinum C2 toxin to enter target cells (25). C2IN-C3 caused rapid disassembly of stress fibers and major changes in morphology in cultured rat astroglial cells and in CHO cells. The effects started within 40 min and were maximal about 2 h after toxin addition. As reported for the effects of the C3 exoenzyme (38, 39), these changes in morphology were preceded by a complete ADP-ribosylation of Rho. Surprisingly, the cells recovered within a few hours after removal of the toxin from the medium. Apparently, this recovery of the normal cell morphology depended on the occurrence of non-ADP-ribosylated RhoA. Concomitantly with the start of the rebuilding of stress fibers, a small amount of non-ADP-ribosylated RhoA was detected. Twenty-four hours after toxin removal, when reconstitution of
the actin cytoskeleton and regeneration of cellular morphology were complete, only non-ADP-ribosylated Rho was observed. Subsequently, we tested whether reappearance of non-ADP-ribosylated Rho resulted from cleavage of the ADP-ribose moiety of modified Rho or from de novo synthesis of the GTPase. Cleavage of arginine-linked ADP-ribose is catalyzed by specific ADP-ribosylarginine hydrolases (40), but ADP-ribosylasparagine hydrolase has not been identified so far. Moreover, we were not able to obtain any evidence for a cleavage of the ADP-ribose moiety attached to Rho by hydrolase activity. In contrast, the translation inhibitors cycloheximide and puromycin blocked de novo synthesis of RhoA and prevented the recovery of cell morphology. This finding strongly suggested that Rho neosynthesis is crucial for reversal of cell morphology. Since Northern blot analysis did not show an increase in RhoA mRNA after treatment with C2IN-C3 or after its removal, the rapid de novo synthesis of RhoA was not due to enhanced transcription. Therefore, we conclude that the constitutive biosynthesis of RhoA is sufficient to restore RhoA functions. Morphological changes were reversed when neosynthesis had provided at approximately 10% of the normal cellular content of Rho but when ADP-ribosylated Rho was still present. Thus, our findings do not support a dominant negative role of ADP-ribosylated Rho as suggested from microinjection studies (39). This discrepancy may be explained by the high protein concentration usually used in such microinjection studies.

In addition to rapid neosynthesis of RhoA, the recovery of normal cell morphology depended on the intracellular degradation of the toxin. Since addition of the proteasome inhibitor lactacystin prevented the recovery of the normal cell morphology, the C2IN-C3 fusion toxin was probably degraded by the proteosomal pathway (41). Similarly, toxin degradation by the proteosomal pathway has been recently described for a fusion protein.

**FIG. 8.** Influence of CNF1 on ADP-ribosylated Rho. CHO cells were treated with the indicated combinations of C2IN-C3 (100 ng/ml)/C2II (200 ng/ml) and GST-CNF1 (300 ng/ml), lysed, and subjected to [32P]ADP-ribosylation by C3 transferase. Autoradiogram of [32P]ADP-ribosylation assay: lane 1, control cells; lane 2, cells incubated for 3 h with C2IN-C3 + C2II; lane 3, cells incubated for 3 h with CNF1; lane 4, cells incubated for 3 h with C2IN-C3 + C2II and subsequently for 3 h with CNF1; lane 5, cells incubated for 3 h with C2IN-C3 + C2II together with CNF1; lane 6, cells incubated for 3 h with CNF1 and subsequently for 3 h with C2IN-C3 + C2II.

**FIG. 9.** Analysis of ADP-ribosylation of Rho in CHO cells after treatment with C2IN-C3/C2II and CNF1. Cells were treated for 16 h with 100 ng/ml C2IN-C3 and 200 ng/ml C2II at 37 °C in the presence of 20 μM cycloheximide. Then GST-CNF1 (300 ng/ml) was added for another 2 h in the presence of cycloheximide. The cells were lysed, and aliquots (50 μg protein) were [32P]ADP-ribosylated by C3 transferase and analyzed by anti-RhoA immunoblot. A, autoradiography of [32P]ADP-ribosylated Rho. B, anti-RhoA immunoblot. Lane 1, control cells; lane 2, 16-h incubation with C2IN-C3/C2II + 20 μM cycloheximide; lane 3, 2-h incubation with CNF1 (in the presence of cycloheximide); lane 4, 6-h incubation with C2IN-C3/C2II followed by 2-h incubation with CNF1 (in the presence of C2IN-C3/C2II and cycloheximide). RhoA, which is ADP-ribosylated and deamidated, is indicated by a double asterisk.

**FIG. 10.** Influence of ADP-ribosylation on nucleotide release of RhoA stimulated by the nucleotide exchange factor LBC. A, control RhoA (Con-RhoA, 0.5 μM) and ADP-ribosylated RhoA (ADPr-RhoA, 0.5 μM) were pre-loaded with mant-GDP and incubated at 37 °C. Release of the bound mant-GDP was started by the addition of 100 μM GTP in the absence (○) or presence of 1 μM GST-LBC (●). Nucleotide exchange was monitored by the decrease in the fluorescence of mant-GDP at 444 nm. Exciting of the mant-fluorophor was at 357 nm. B, plot of the rate constants for release of mant-GDP of control RhoA (○) and of ADP-ribosylated RhoA (●) determined at the indicated concentrations of LBC.

Reversal of Cytopathic Effects of ADP-ribosylated Rho 27412
Prevented the cytopathic effects of C3B, a C3 fusion toxin consisting of C3 and the binding/translocation domain of diphtheria toxin (43). In this report it was suggested that CNF1 prevents ADP-ribosylation of Rho by C3 (43). In contrast, our data indicate that ADP-ribosylation and deamidation of Rho by CNF1 and C3, respectively, occur in parallel, but the functional consequences induced by CNF1 appear to be dominant. In addition to Rho, CNF1 was shown to deamidate and to activate Rac and Cdc42 (17). Also these GTPases are involved in organization of the actin cytoskeleton. However, there is no evidence that Rac and Cdc42 can substitute for Rho as regards the formation of stress fibers (2, 3). Therefore, our findings suggest that CNF1 induced the formation of an activated form of ADP-ribosylated Rho, which still interacted with cellular targets and was capable of activating effectors necessary for the formation of stress fibers and focal adhesions.

Moreover, this observation provides new insights into the molecular mechanism underlying the inactivation of Rho by ADP-ribosylation. It was shown that ADP-ribosylation has no major effects on nucleotide binding as well as hydrolysis of bound GTP. GAP-stimulated GTPase activity is not affected either (39, 44). Because the ADP-ribosylation at Asn41 occurs near the effector region of Rho, it has been suggested that the ADP-ribosylation blocks the interaction of Rho with its effectors (22). However, this hypothesis was not supported by findings that ADP-ribosylated Rho interacts with effectors like protein kinase N (44) or phosphatidyl-4-phosphate 5-kinase (45). Based on the observation that ADP-ribosylated Rho binds with even higher affinity to phosphatidyl-4-phosphate 5-kinase than the native RhoA, it was speculated that the effector activation step but not the binding is blocked by ADP-ribosylation (45). Our findings suggested that rather the activation step of Rho is crucially altered by ADP-ribosylation. This hypothesis was supported by the in vitro studies with recombinant ADP-ribosylated RhoA, showing that the stimulation of the GDP release from Rho by the guanine nucleotide exchange factor LBC was inhibited after ADP-ribosylation. Because the inactivation mechanism of ADP-ribosylated Rho by GTP hydrolysis is fully functional, a blocked or diminished activation of Rho will shift the GTPase to its inactive state (Fig. 11). Thus, after inhibition of the GTPase activity of Rho by CNF1, ADP-ribosylated Rho becomes active because the equilibrium between the inactive and active state is again shifted to the active state (Fig. 11).

Acknowledgments—We gratefully acknowledge the excellent technical assistance of Ulrike Müller and Brigitte Neufang.

REFERENCES
1. Hall, A. (1998) Science 279, 509–514
2. Ridley, A. J., and Hall, A. (1992) Cell 70, 389–399
3. Ridley, A. J., Paterson, H. F., Johnstone, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401–410
4. Nobes, C. D., and Hall, A. (1995) Cell 81, 53–62
5. Zeeuwen, P. L. J. M., Hendriks, W., de Jong, W. W., and Schalkwijk, J. (1997) J. Biol. Chem. 272, 20471–20478
6. Prepens, U., Just, I., Von Eichel-Streiber, C., and Aktories, K. (1996) J. Biol. Chem. 271, 7234–7239
7. Caron, E., and Hall, A. (1998) Science 282, 1717–1721
8. Lamaze, C., Chuang, T. H., Terlecky, L. J., Bokoch, G. M., and Schmid, S. L. (1996) Nature 382, 177–179
9. Schmalzing, G., Richter, H. P., Hansen, A., Schwarz, W., Just, I., and Aktories, K. (1995) J. Cell Biol. 130, 1319–1332
10. Olson, M. F., Ashworth, A., and Hall, A. (1995) Science 269, 1270–1272
11. Reuser, K. H., Wiederhold, M., Dunker, P., Just, I., Bohle, R. M., Kruger, M., and Katz, N. (1995) Eur. J. Biochem. 230, 32–37
12. Khosravi-Far, R., Solaki, P. A., Clark, G. J., Kinch, M. S., and Der, C. J. (1995) Mol. Cell. Biol. 15, 6433–6453
13. Aktories, K. (1997) Trends Microbiol. 5, 282–288
14. Just, I., Seiler, J., Wilm, M., Von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500–503
15. Just, I., Wilm, M., Seiler, J., Rex, G., Von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) J. Biol. Chem. 270, 13932–13936
16. Schmidt, G., Sehr, P., Wilm, M., Seiler, J., Mann, M., and Aktories, K. (1997) Nature 387, 725–729
